Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering
Details : XEN496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).
Product Name : XEN496
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 03, 2021
Details : Xenon has received a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), which recommends the granting of an orphan medicinal product designation for XEN496 for the treatment of KCNQ2-DEE.
Product Name : XEN496
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 10, 2020
Reset All
